Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Get Free Report) saw a large decrease in short interest during the month of November. As of November 15th, there was short interest totalling 11,400 shares, a decrease of 46.0% from the October 31st total of 21,100 shares. Approximately 2.1% of the company’s stock are short sold. Based on an average daily trading volume, of 336,800 shares, the days-to-cover ratio is currently 0.0 days.
Hedge Funds Weigh In On Bluejay Diagnostics
An institutional investor recently raised its position in Bluejay Diagnostics stock. Anson Funds Management LP boosted its holdings in shares of Bluejay Diagnostics, Inc. (NASDAQ:BJDX – Free Report) by 359.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 319,280 shares of the company’s stock after purchasing an additional 249,770 shares during the period. Anson Funds Management LP owned approximately 1.93% of Bluejay Diagnostics worth $41,000 at the end of the most recent quarter. Institutional investors own 18.47% of the company’s stock.
Bluejay Diagnostics Stock Down 3.9 %
Shares of NASDAQ:BJDX traded down $0.14 during trading on Thursday, hitting $3.48. 19,702 shares of the company traded hands, compared to its average volume of 104,163. The stock has a market capitalization of $1.88 million, a price-to-earnings ratio of 0.00 and a beta of 0.73. The business’s fifty day moving average is $5.26 and its 200-day moving average is $54.77. Bluejay Diagnostics has a one year low of $3.03 and a one year high of $1,564.00.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.
Recommended Stories
- Five stocks we like better than Bluejay Diagnostics
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Differences Between Momentum Investing and Long Term Investing
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Investors Need to Know to Beat the Market
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
